Arcus Biosciences Inc. (RCUS)
Arcus Biosciences Inc. (RCUS) Stock Price, Analysis & Data
| Bid | 29.38 |
| Market Cap | 3.72B |
| Revenue (ttm) | 117M |
| Net Income (ttm) | -460M |
| Beta | 0.81 |
| EPS (ttm) | -3.94 |
| PE Ratio (ttm) | n/a |
| Forward PE | -9.09 |
| P/B (ttm) | 8.09 |
| P/S (ttm) | 32.18 |
| Earnings Date | Aug 6, 2025 |
| Ask | 29.4 |
| Volume | 1,686,840 |
| Avg. Volume (20D) | 1,254,116 |
| Open | 29.32 |
| Previous Close | 29.48 |
| Day's Range | 28.92 - 29.98 |
| 52-Week Range | 9.81 - 31.73 |
| Analyst | Strong Buy |
| Price Target | 42.5 (43.73%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About RCUS
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclusta...
Financial Performance
In 2025, Arcus Biosciences's revenue was 247M, a decrease of -4.26% compared to the previous year's 258M. Earnings were -353M, an increase of 24.73%.
Financial StatementsAnalyst Forecast
According to 12 analyst ratings, the average rating for RCUS stock is "Strong Buy". The 12-month stock price forecast is 42.5, which is upside of 43.73% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
